Write your message
Volume 7, Issue 1 (Winter 2022)                   J Obstet Gynecol Cancer Res 2022, 7(1): 1-6 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Naseri A, Seyedi Sahebari S, Hosseini M. Pharmacotherapy of COVID-19: Considerations for Pregnancy and Breastfeeding. J Obstet Gynecol Cancer Res. 2022; 7 (1) :1-6
URL: http://jogcr.com/article-1-396-en.html
1- Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
2- Emergency Medicine Research Team, Tabriz University of Medical Sciences, Tabriz, Iran , hosseini.msalar@gmail.com
Abstract:   (244 Views)
The coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a chief concern of the international community. As of May 2021, more than 150 million cases and 3.2 million deaths have been recorded. Considering the early struggle in treating COVID-19 patients, the researchers and clinicians have decided to try the previously available drugs according to their mechanisms of action. This article aims to review the potential drugs for COVID-19 patients during pregnancy and breastfeeding and their safety. PubMed and Scopus databases and Google Scholar engine were searched with the proper combination of the free keywords and MeSH Terms of COVID-19, SARS-CoV-2, Pregnancy, Breastfeeding, Treatment, Pharmacotherapy, Drug Therapy, and Drug Safety. All relevant clinical studies published until the end of 2020 were included in this review. Many antivirals, antibiotics, antiparasitics, and antipyretics have been proposed, but most of them are not registered for COVID-19 or have demonstrated little effect on the disease. Since there is still a long way to find an effective drug for the treatment of COVID-19, prevention is currently the most effective way. Also, prescribing drugs to these two groups of patients should be done according to the safety recommendations.
Full-Text [PDF 347 kb]   (15 Downloads) |   |   Full-Text (HTML)  (19 Views)  
Systematic Review: Review | Subject: Obstetrics and Gynecology
Received: 2021/05/15 | Accepted: 2021/06/7 | Published: 2021/09/9

1. Lancet T. Emerging understandings of 2019-nCoV. Lancet (London, England). 2020;395(10221):311. [DOI:10.1016/S0140-6736(20)30186-0]
2. WHO Coronavirus (COVID-19) Dashboard [Available from: https://covid19.who.int/.
3. Oliveira LV, Silva C, Lopes LP, Agra IKR. Current evidence of SARS-CoV-2 vertical transmission: an integrative review. Rev Assoc Med Bras (1992). 2020;66Suppl 2(Suppl 2):130-5. [DOI:10.1590/1806-9282.66.s2.130]
4. Monteiro WM, Brito-Sousa JD, Baía-da-Silva D, Melo GCd, Siqueira AM, Val F, et al. Driving forces for COVID-19 clinical trials using chloroquine: the need to choose the right research questions and outcomes. Revista da Sociedade Brasileira de Medicina Tropical. 2020;53. [DOI:10.1590/0037-8682-0155-2020]
5. Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015;23(5):231-69. [DOI:10.1007/s10787-015-0239-y]
6. Drugs Co. The transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108(3):776-89. [DOI:10.1542/peds.108.3.776]
7. Consortium WHOST, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, et al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2021;384(6):497-511. [DOI:10.1056/NEJMoa2023184]
8. Bleyzac N, Goutelle S, Bourguignon L, Tod M. Azithromycin for COVID-19: More Than Just an Antimicrobial? : Springer; 2020. [DOI:10.1007/s40261-020-00933-3]
9. Gautret P, Lagier J-C, Parola P, Meddeb L, Mailhe M, Doudier B, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. International journal of antimicrobial agents. 2020:105949. [DOI:10.1016/j.ijantimicag.2020.105949]
10. Abubakar AR, Sani IH, Godman B, Kumar S, Islam S, Jahan I, et al. Systematic Review on the Therapeutic Options for COVID-19: Clinical Evidence of Drug Efficacy and Implications. Infect Drug Resist. 2020;13:4673-95. [DOI:10.2147/IDR.S289037]
11. Furtado RHM, Berwanger O, Fonseca HA, Correa TD, Ferraz LR, Lapa MG, et al. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet. 2020;396(10256):959-67. [DOI:10.1016/S0140-6736(20)31862-6]
12. Published by IDSA on 4/11/2020. Last updated. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19.
13. Keskin-Arslan E, Kaplan YC, Koren G. Use of azithromycin during pregnancy and breastfeeding: A coronavirus pan-demic (COVID-19) update. 2020.
14. WHO. WHO recommends against the use of remdesivir in COVID-19 patients. 20 November 2020.
15. fda. Remdesivir (Veklury) Approval for the Treatment of COVID-19-The Evidence for Safety and Efficacy. 11/25/2020.
16. Maldarelli GA, Savage M, Mazur S, Oxford-Horrey C, Salvatore M, Marks KM. Remdesivir Treatment for Severe COVID-19 in Third-Trimester Pregnancy: Case Report and Management Discussion. Open Forum Infect Dis. 2020;7(9):ofaa345. [DOI:10.1093/ofid/ofaa345]
17. Berghella V, Hughes B. Coronavirus disease 2019 (COVID-19): Pregnancy issues and antenatal care.
18. Burwick RM, Yawetz S, Stephenson KE, Collier AY, Sen P, Blackburn BG, et al. Compassionate Use of Remdesivir in Pregnant Women with Severe Covid-19. Clin Infect Dis. 2020.
19. Anderson PO. Antivirals for COVID-19 and Breastfeeding. Breastfeed Med. 2020;15(10):605-7. [DOI:10.1089/bfm.2020.0268]
20. Pasley MV, Martinez M, Hermes A, d'Amico R, Nilius A. Safety and efficacy of lopinavir/ritonavir during pregnancy: a systematic review. AIDS Rev. 2013;15(1):38-48.
21. Levonorgestrel I. Drugs and Lactation Database (LactMed)[Internet]. Bethesda (MD): National Library of Medicine (US). 2019:63-7.
22. Louchet M, Sibiude J, Peytavin G, Picone O, Treluyer JM, Mandelbrot L. Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019. Am J Obstet Gynecol MFM. 2020;2(3):100159. [DOI:10.1016/j.ajogmf.2020.100159]
23. Chen C, Huang J, Cheng Z, Wu J, Chen S, Zhang Y, et al. Favipiravir versus arbidol for COVID-19: a randomized clinical trial. MedRxiv. 2020. [DOI:10.1101/2020.03.17.20037432]
24. Wei FF, Moradkhani A, Hemmati Hezaveh H, Miraboutalebi SA, Salehi L. Evaluating the Treatment with Favipiravir in Patients Infected by COVID-19: A Systematic Review and Meta-analysis. International Journal of Scientific Research in Dental and Medical Sciences. 2020;2(3):87-91.
25. Agrawal U, Raju R, Udwadia ZF. Favipiravir: A new and emerging antiviral option in COVID-19. Med J Armed Forces India. 2020;76(4):370-6. [DOI:10.1016/j.mjafi.2020.08.004]
26. Hayden FG, Shindo N. Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis. 2019;32(2):176-86. [DOI:10.1097/QCO.0000000000000532]
27. Payandemehr P, Azhdarzadeh M, Bahrami-Motlagh H, Hadadi A, Najmeddin F, Shahmirzaei S, et al. Interferon beta-1a as a Candidate for COVID-19 Treatment; An Open-Label Single-Arm Clinical Trial. Advanced Journal of Emergency Medicine. 2020;4(2s):e51-e.
28. Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9(2):196-206. [DOI:10.1016/S2213-2600(20)30511-7]
29. Peiffer-Smadja N, Yazdanpanah Y. Nebulised interferon beta-1a for patients with COVID-19. Lancet Respir Med. 2021;9(2):122-3. [DOI:10.1016/S2213-2600(20)30523-3]
30. Bosi E, Bosi C, Rovere Querini P, Mancini N, Calori G, Ruggeri A, et al. Interferon beta-1a (IFNbeta-1a) in COVID-19 patients (INTERCOP): study protocol for a randomized controlled trial. Trials. 2020;21(1):939. [DOI:10.1186/s13063-020-04864-4]
31. FDA. Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19 2020 [Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19.
32. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021;384(9):795-807. [DOI:10.1056/NEJMoa2031994]
33. Costanzo G, Firinu D, Losa F, Deidda M, Barca MP, Del Giacco S. Baricitinib exposure during pregnancy in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2020;12:1759720X19899296. [DOI:10.1177/1759720X19899296]
34. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9. [DOI:10.1001/jama.2020.1585]
35. Le Gouez A, Benachi A, Mercier FJ. Fever and pregnancy. Anaesth Crit Care Pain Med. 2016;35 Suppl 1:S5-S12. [DOI:10.1016/j.accpm.2016.06.007]
36. Edwards MJ. Review: Hyperthermia and fever during pregnancy. Birth Defects Res A Clin Mol Teratol. 2006;76(7):507-16. [DOI:10.1002/bdra.20277]
37. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? The Lancet Respiratory Medicine. 2020;8(4):e21. [DOI:10.1016/S2213-2600(20)30116-8]
38. Day M. Covid-19: ibuprofen should not be used for managing symptoms, say doctors and scientists. British Medical Journal Publishing Group; 2020. [DOI:10.1136/bmj.m1086]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License Journal of Obstetrics, Gynecology and Cancer Research by Farname Inc is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. Based on a work at http://jogcr.com/.

© 2021 CC BY-NC 4.0 | Journal of Obstetrics, Gynecology and Cancer Research (JOGCR)

Designed & Developed by : Yektaweb | Piblisher: Farname Inc.